1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Patient Centric Pharma: Restructuring business for better outcomes




Is “patient centricity” a passing fad? Experts say it’s here to stay. In fact, it’s been called a “strategic necessity.” Companies like Pfizer and Sanofi know it. Patient Centric Pharma gives you an insider’s look at how they and others are using patient centricity to build business and cement relationships, and what you need to do to compete.

Contributors include executives from Boehringer Ingelheim, Merck Serono, UCB and others. Case studies and examples are drawn from experiences at AbbVie, AstraZeneca, Novo Nordisk, and Vertex, in addition to Pfizer and Sanofi.







Top Takeaways

Meet customer expectations: See what we can learn from companies outside pharma like Amazon about customer engagement and responsiveness.
The value of patient centricity: Find out the factors that make this model the valuable modern approach to business pharma needs and not just a buzzword.
Be more relevant: Gain strategic advantage by understanding how to be more relevant to patients.
Gain organization-wide commitment: How to get support from senior management to ensure there is a “patient centricity team” and “Chief Patient Officer” in the future of your business.
Experts tell us the barriers to patient centricity: Know the internal and external barriers to patient centricity, how to overcome them, and why you should bother.
The benefits of patient collaboration: How to better collaborate with patients and benefit from the experience.
Improve product life cycle: How to use patient engagement and input throughout your organisation and across the lifecycles of your brands.



Key Issues Explored

The critical relationship between patient centricity and customer expectations in 21st century commerce.
Strategies and techniques for overcoming internal and external barriers to patient centricity.
Patient centricity is more than an attitude; it’s a pathway to valuable business information.
Patient centricity merits and requires the support of senior management and an organization-wide commitment. Have you got that at your company? If not, how can you get it?
How to measure and assess patient centricity.
Patient centricity is now a factor from early stage drug development to implementation of patient support programmes.
The future of patient centricity and how to prepare for it.
Is there a “patient centricity team” or “Chief Patient Officer” in your future? Should there be?
Patients’ expectations are growing. They’re comparing you to Amazon. Your “patient centricity” needs to keep pace.
Assess patient expectations of you and your organisation and implement the programs that will help you meet them.
What are the most important elements of a patient-centric strategy?
How to effectively leverage patient engagement and input throughout your organisation and across the lifecycles of your brands.


Who needs this report

This report will benefit anyone with responsibilities in the following areas:

Marketing

Product/Brand Management

Digital/Multichannel Marketing

Commercial Innovation/Excellence

Key Account Management

Patient Advocacy Relations

Patient Experience/Engagement

Patient Recruitment/Patient Access

Medical Communications

Medical Affairs

Lifecycle Management

Regulatory/Compliance


Contributors

AbbVie
AstraZeneca
Boehringer Ingelheim
Merck Serono
Novo Nordisk
Pfizer
Sanofi
UCB
Vertex



About FirstWord Reports

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence



FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


Table Of Contents

Patient Centric Pharma: Restructuring business for better outcomes
1.Executive summary
2.Research objectives and methodology
3.Contributors
4.Patient centricity overview
5.Key findings
6.Definition of patient centricity
7.Importance of patient centricity
8.How patient-centric is pharma?
9.Several companies are seen to be leading the way
10.Organisation within pharma
11.Key findings
12.‘Patient-centric' roles vary between companies
13.Stakeholder engagement
14.Key findings
15.Companies are largely engaging with advocacy groups
16.Insight generation is one of the most important roles for patients
17.Early engagement is key for patient involvement
18.Barriers to becoming patient-centric
19.Key findings
20.Internal barriers can prevent true patient-centricity being embedded
21.Regulatory and compliance issues are commonly seen as barriers
22.There are several external factors that can hinder patient-centricity
23.Future outlook
24.Key findings
25.Patient-centricity will continue to drive pharma strategy
26.Patient-centric roles are likely to become more common
27.Collaboration with other industries will help advance patient?centricity
28.There are several key recommendations for patient-centricity

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.